Pacira BioSciences Reports Full-Year and Fourth Quarter 2021 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Pacira BioSciences Reports Full-Year and Fourth Quarter 2021 Financial Results

Pacira Pharmaceuticals (PCRX) PT Raised to $67 at BMO Capital

February 28, 2022 8:49 AM EST

BMO Capital analyst Gary Nachman raised the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $67.00 (from $62.00) while maintaining a Market Perform rating following results.

The analyst commented, "4Q beat although rev. was preannounced, but margin improvement coming through and should accelerate following... More

Pacira Pharma (PCRX) Tops Q4 EPS by 9c

February 24, 2022 8:04 AM EST

Pacira Pharma (NASDAQ: PCRX) reported Q4 EPS of $0.99, $0.09 better than the analyst estimate of $0.90. Revenue for the quarter came in at $159.2 million versus the consensus estimate of $155.74 million.

GUIDANCE:

Today the company is providing full-year 2022 operating expense guidance as... More